Robert Alter, MD, reviews the CheckMate 9ER trial of cabozantinib/nivolumab versus sunitinib in advanced renal cell cancer.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.